Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18792077 | COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOF | August 2024 | June 2025 | Allow | 10 | 3 | 0 | Yes | No |
| 18680557 | AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSES | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18609604 | TREATMENT OF HEARING LOSS | March 2024 | October 2024 | Allow | 7 | 0 | 0 | No | No |
| 18687295 | PHARMACEUTICAL COMPOSITION | February 2024 | March 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18424626 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | January 2024 | March 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18420540 | METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTH | January 2024 | April 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18417312 | LIQUID COMPOSITION COMPRISING GLUCOSE | January 2024 | August 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18397012 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | December 2023 | January 2025 | Abandon | 13 | 1 | 0 | Yes | No |
| 18528550 | Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With Radiation | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18527321 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | December 2023 | January 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18522850 | BODY MILK | November 2023 | September 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18521467 | PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACID | November 2023 | June 2025 | Allow | 19 | 2 | 0 | No | No |
| 18504043 | NUTRITIONAL COMPOSITIONS WITH MFGM AND CERTAIN HUMAN MILK OLIGOSACCHARIDES AND USES THEREOF | November 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18555982 | USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAIN | October 2023 | March 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18378985 | PERITONEAL DIALYSIS SOLUTION | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18476119 | METHODS AND COMPOSITIONS FOR EXTENDING LIFESPAN | September 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18237659 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | August 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18362656 | COMPOSITE VITAMIN COMPOSITION PROMOTING GASTROINTESTINAL SYSTEM MOTILITY | July 2023 | April 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18274166 | CONJUGATES WITH INHIBITORY RECEPTOR LIGANDS TO INDUCE ANERGY IN INSULIN-BINDING B CELLS | July 2023 | July 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18336419 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18132332 | ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD | April 2023 | February 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18131161 | TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE | April 2023 | October 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18130475 | TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATION | April 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18181653 | NUTRITIONAL COMPOSITION FOR IMPROVING CELL MEMBRANES | March 2023 | June 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18176631 | GLYCOCONJUGATION PROCESS | March 2023 | October 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17983992 | COMPOSITIONS COMPRISING AT LEAST ONE N-ACETYLATED AND AT LEAST ONE FUCOSYLATED OLIGOSACCHARIDE FOR USE IN THE PROMOTION OF DIGESTIVE CAPACITY IN INFANTS AND YOUNG CHILDREN | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17804679 | IMMUNOGENIC COMPOSITION | May 2022 | June 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17772291 | ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD | April 2022 | January 2025 | Allow | 33 | 2 | 0 | No | No |
| 17765059 | TREHALOSE FORMULATIONS AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 0 | 0 | No | No |
| 17676675 | METHOD FOR DEACETYLATION OF BIOPOLYMERS | February 2022 | March 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17633869 | a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITOR | February 2022 | June 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17586381 | XYLOOLIGOSACCHARIDE AS A MULTIFUNCTIONAL PREBIOTIC | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17628857 | TREATMENT COMPRISING SGLT INHIBITORS | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17625394 | FOOD COMPOSITION | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17615479 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-COELIAC WHEAT AND / OR GLUTEN SENSITIVITY | November 2021 | January 2025 | Abandon | 38 | 0 | 0 | No | No |
| 17610951 | USE OF GINSENOSIDE M1 FOR TREATING CANCER | November 2021 | February 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17608837 | CHLORIDE INTRACELLULAR CHANNEL 1 FOR REGULATION OF FOOD INTAKE | November 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17608203 | COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOF | November 2021 | January 2025 | Allow | 39 | 1 | 0 | No | No |
| 17606313 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES | October 2021 | January 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17506227 | GLUCOSE INFUSION SOLUTION COMPOSITION | October 2021 | June 2025 | Allow | 43 | 4 | 0 | No | No |
| 17472604 | AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSES | September 2021 | April 2024 | Allow | 31 | 4 | 0 | Yes | No |
| 17435629 | METHOD AND KIT FOR DETECTING INFLUENZA VIRUS, AND METHOD FOR DIAGNOSING INFLUENZA VIRUS INFECTION | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17419068 | BRAIN-PENETRATING LIGAND AND DRUG CARRIER | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17418570 | HEAT STRESS RELIEVING AGENT | June 2021 | April 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17417049 | COMPOSITION AND METHOD FOR PROMOTING INTESTINAL BARRIER HEALING | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17292963 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | May 2021 | February 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17291481 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS | May 2021 | November 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17286803 | PHARMACEUTICAL USE OF ANEMOSIDE B4 AGAINST ACUTE GOUTY ARTHRITIS | April 2021 | January 2025 | Allow | 45 | 2 | 0 | No | No |
| 17285675 | USE OF SGLT2 INHIBITORS TO TREAT PRIMARY SCLEROSING CHOLANGITIS | April 2021 | June 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17281598 | Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia | March 2021 | December 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17278467 | TARGETED DRUG DELIVERY SYSTEM TO BE USED IN TREATING OSTEOMYELITIS | March 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17277534 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | March 2021 | September 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17268655 | TREATMENT FOR GENE REACTIVATION | February 2021 | November 2024 | Allow | 45 | 2 | 0 | No | No |
| 17267538 | CELLULOSE ACETATE COMPOSITION AND MOLDED ARTICLE | February 2021 | November 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17259013 | Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer Agent | January 2021 | May 2024 | Allow | 40 | 1 | 0 | No | No |
| 17251493 | Application Of Xylan In The Preparation Of Drugs Or Food For Preventing Or Treating Osteoporosis | January 2021 | December 2024 | Abandon | 48 | 2 | 0 | Yes | No |
| 17253781 | ANTI-RETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | December 2020 | October 2024 | Allow | 46 | 2 | 1 | No | No |
| 17058562 | LIPID-MODIFIED NUCLEIC ACID COMPOUNDS AND METHODS | November 2020 | June 2025 | Abandon | 55 | 1 | 1 | No | No |
| 17055446 | METHOD OF TREATING MALIGNANT TUMOR BY AZABICYCLIC COMPOUND | November 2020 | March 2024 | Allow | 40 | 1 | 0 | No | No |
| 17049646 | NOVEL MOGROSIDES, METHODS OF OBTAINING THE SAME, AND USES | October 2020 | June 2024 | Allow | 44 | 0 | 0 | Yes | No |
| 17041175 | NOVEL SAPONIN ADJUVANT AND EVALUATION METHOD THEREOF | September 2020 | November 2024 | Allow | 50 | 2 | 1 | No | No |
| 17018975 | VACCINE SYSTEM FOR VACCINE ADJUVANT | September 2020 | April 2022 | Abandon | 19 | 6 | 0 | No | No |
| 16984626 | PREPARATION METHOD OF 4D CHITOSAN-BASED THERMOSENSITIVE HYDROGEL | August 2020 | January 2025 | Allow | 54 | 5 | 0 | Yes | No |
| 16053354 | DRUG COMPOUND AND PURIFICATION METHODS THEREOF | August 2018 | September 2019 | Allow | 14 | 0 | 0 | Yes | No |
| 15771941 | PHARMACEUTICAL COMPOSITION, USE OF MEFLOQUINE IN A FIXED DOSE, AND METHOD FOR TREATING TUBERCULOSIS | April 2018 | February 2020 | Allow | 22 | 2 | 0 | No | No |
| 15579481 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS | December 2017 | April 2020 | Allow | 28 | 2 | 0 | Yes | No |
| 15575787 | ANTICANCER ADJUVANT CONTAINING PANAXADIOL GINSENOCIDE COMPOUND | November 2017 | August 2019 | Allow | 21 | 2 | 0 | No | No |
| 15564994 | GLYCOSAMINOGLYCAN ESTERS, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN FORMULATIONS FOR OPHTHALMIC USE | October 2017 | February 2019 | Allow | 16 | 1 | 0 | Yes | No |
| 15129149 | Solid Composition Comprising Amorphous Sofosbuvir | September 2016 | August 2019 | Allow | 34 | 2 | 1 | Yes | No |
| 15123359 | HYALURONIC ACID MODIFIED BY SPHINGOSINE-1-PHOSPHORIC ACID | September 2016 | June 2019 | Allow | 33 | 3 | 0 | Yes | No |
| 14785814 | AQUEOUS OPHTHALMIC FORMULATIONS BASED ON AZITHROMYCIN | October 2015 | February 2019 | Allow | 40 | 3 | 0 | No | No |
| 14780423 | GLYCOGEN-BASED WATER SOLUBILITY ENHANCERS | September 2015 | February 2020 | Allow | 52 | 6 | 0 | Yes | No |
| 14758589 | ALGINATE COMPOSITIONS AND USES THEREOF | June 2015 | August 2019 | Allow | 50 | 4 | 0 | Yes | No |
| 14162253 | Phenolic Coatings and Methods of Making and Using Same | January 2014 | August 2018 | Allow | 55 | 6 | 0 | Yes | No |
| 13515152 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | September 2012 | August 2018 | Allow | 60 | 4 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLER, DALE R.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MILLER, DALE R works in Art Unit 1693 and has examined 68 patent applications in our dataset. With an allowance rate of 69.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner MILLER, DALE R's allowance rate of 69.1% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MILLER, DALE R receive 1.71 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MILLER, DALE R is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.9% benefit to allowance rate for applications examined by MILLER, DALE R. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.7% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.